-+ 0.00%
-+ 0.00%
-+ 0.00%

China Biopharmaceutical announced that the recombinant fusion protein in the national class 1 innovative drug IM-101 injection developed by Zhengda Tianqing, a subsidiary of the group, has obtained clinical trial approval from the China National Drug Administration and is intended to be used to treat chronic hepatitis B.

Zhitongcaijing·07/23/2026 09:49:05
Listen to the news
China Biopharmaceutical announced that the recombinant fusion protein in the national class 1 innovative drug IM-101 injection developed by Zhengda Tianqing, a subsidiary of the group, has obtained clinical trial approval from the China National Drug Administration and is intended to be used to treat chronic hepatitis B.